Who is eligible for clinical trial NCT02477696?

Participants must meet protocol criteria for Chronic Lymphocytic Leukemia. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02477696 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-21

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) (NCT02477696)

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Acerta Pharma BV

🩺 Plain-English Summary (8th-Grade Level)

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.

Who can join: Review the eligibility criteria below.

Location: Research Site — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (130 Sites)

Showing the first 25 of 130 sites.

Research Site — Phoenix, Arizona
Research Site — Anaheim, California
Research Site — Berkeley, California
Research Site — Duarte, California
Research Site — La Jolla, California
Research Site — Los Angeles, California
Research Site — Palo Alto, California
Research Site — Santa Rosa, California
Research Site — Jacksonville, Florida
Research Site — Tampa, Florida
Research Site — Athens, Georgia
Research Site — Harvey, Illinois
Research Site — Peoria, Illinois
Research Site — Wichita, Kansas
Research Site — Minneapolis, Minnesota
Research Site — Rochester, Minnesota
Research Site — Billings, Montana
Research Site — Hackensack, New Jersey
Research Site — Lake Success, New York
Research Site — New Hyde Park, New York
Research Site — New York, New York
Research Site — New York, New York
Research Site — New York, New York
Research Site — Durham, North Carolina
Research Site — Columbus, Ohio

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Lymphocytic Leukemia

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona

Explore by condition: All Chronic Lymphocytic Leukemia clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗